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Abstract: Background: Young adults with perinatally acquired HIV (PAH) face several challenges, including
adhering to antiretroviral therapy (ART), managing the risk of onward HIV transmission and maintaining positive
well-being. Sharing one’s HIV status with others (onward HIV disclosure) may assist with these challenges by
facilitating emotional and practical support. Rates of HIV status sharing are, however, low in this population. There
are no existing interventions focused on sharing one’s HIV status for young adults living with PAH. The HEADS-UP
study is designed to develop and test the feasibility of an intervention to help the sharing of HIV status for young
adults with PAH.
Methods: The study is a 30-month multi-site randomised feasibility study across both a high-income/low-HIV
prevalence country (UK) and a low-income/high-HIV prevalence country (Uganda). Phase 1 (12 months) will involve
developing the intervention using qualitative interviews with 20 young people living with PAH (ten in the UK—18
to 29 years; ten in Uganda—18 to 25 years), 20 of their social network (friends, family, sexual partners as defined by
the young person; ten in the UK, ten in Uganda) and ten professionals with experience working with young adults
with PAH (five in the UK, five in Uganda). Phase 2 (18 months) involves conducting a randomised feasibility parallel
group trial of the intervention alongside current standard of care condition in each country (main study) with 18-
to 25-year olds with PAH. A sample size of 94 participants per condition (intervention or standard of care; 188
participants in total: 47 in each condition in each country) with data at both the baseline and 6-month follow-up
time points, across UK and Ugandan sites will be recruited. Participants in the intervention condition will also
complete measures immediately post-intervention. Face-to-face interviews will be conducted with ten participants
in both countries immediately post-intervention and at 6-month follow-up (sub-study).
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Discussion: This study will be the first trial that we are aware of to address important gaps in understanding
acceptable and feasible ways of delivering HIV status sharing support for young people living with PAH.
Trial registration: ISRCTN Registry, ISRCTN31852047, Registered on 21 January, 2019. Study sponsor: Royal
Holloway University of London. Sponsor contact: alicen.nickson@rhul.ac.uk. Date and version: April 2020. Protocol
version 3.5.
Keywords: HIV, Disclosure, Perinatal, Feasibility, Intervention
Background
The World Health Organisation estimates that glo-
bally, around 5 million young people (15–25 years) are
living with HIV, and a significant proportion of these
have acquired HIV perinatally (perinatally acquired
HIV (PAH)) [1]. In some low-income countries,
young people are disproportionately affected by HIV.
For example, in Uganda, youth (aged 10–24) comprise
33% of the population, but account for nearly 50% of
the people living with HIV in the country [2]. About
78% of young people aged 15–24 living with HIV res-
ide in sub-Saharan Africa [3].
The enhanced availability of antiretroviral therapy
(ART), as well as the change in ART guidelines since
2015 [4], recommending ART for all people living with
HIV irrespective of CD4 count or clinical stage, has led
to a growing proportion of perinatally HIV-infected chil-
dren surviving into adulthood [5]. The UK has a rela-
tively small number of people living with PAH
compared with other countries globally [5]. The majority
of the UK cohort is of sub-Saharan African origin, with
half born outside the UK [6]. Uganda has a much larger
number of people living with PAH, although there are
no precise estimates of the size of this population [7].
Although young people living with PAH share some
similar challenges to those who are behaviourally in-
fected (e.g., potentially compromised health and risk of
onward transmission through sex) other stressors relate
specifically to perinatal transmission. Longstanding HIV
infection acquired prior to physiological and immuno-
logical development results in distinctive chronic clinical
complications that can cause severe morbidity [8]. In
addition to dealing with chronic illness and its associated
stressors (e.g., hospitalisations, missed school and social
opportunities, and pain), young people living with PAH
face specific unique additional difficulties around ART
adherence and well-being, stemming from multiple care-
taking transitions and loss due to parental illness or
death, loss of siblings, stigma and discrimination, con-
frontation with mortality and an uncertain future [8].
The current generation of young adults with PAH
have often additionally experienced suboptimal ART
regimens, many being born in the era of mono- and
dual-antiretroviral therapy, thus increasing their
likelihood of drug resistance [9]. Rates of viral suppres-
sion are variable globally, associated with poor ART ad-
herence [10]. Adherence to ART remains unsatisfactory
and varies between 27% and 80% across different popu-
lations in various studies [11]. A systematic review of 50
studies from 53 countries reported a pooled level of 62%
good adherence (mostly assessed in relation to viral sup-
pression) among youth [10]. There is evidence of higher
levels of adherence in some recent studies. For example,
of young adults living with PAH who attended a tertiary
youth-friendly service in London, UK, 81% had an un-
detectable viral load (< 200 copies RNA/ml) [12]. Despite
improvements in viral suppression rates across specific
subpopulations, the lowest rates of viral suppression are
among young people aged 13–24 when compared with
younger children or older adults [9]. A recent UK cohort
study found that adolescents with HIV had poorer out-
comes on ART (viral suppression and good immune sta-
tus) compared with younger children [13]. This trend of
poor outcomes has been observed to continue in young
adults with perinatal HIV following transition to adult
care, and data show lower rates of ART uptake in young
adults living with PAH compared with youth with be-
havioural acquisition [14, 15] highlighting a key popula-
tion who may need additional support to achieve the
same level of treatment success [13].
ART adherence is dependent on retention in care.
There are particular challenges in eastern and southern
Africa to retaining people living with HIV in care, with a
large number lost to follow up after initiating treatment,
particularly for young people [16]. In this region, the
proportion of all people with HIV who knew their status
was 85% in 2018 with an estimated 67% on treatment,
and 58% virally suppressed (up from 43% in 2015).
There is a shortage of evidence on the most effective ap-
proaches for young people living with PAH failing to
achieve or sustain viral suppression due to non-
adherence [17].
Unprotected sexual intercourse in young people living
with HIV in the context of globally variable ART cover-
age and low rates of viral suppression [18] presents a
risk of onward (potentially drug resistant) HIV transmis-
sion to partners and to offspring. For many young
adults, regardless of their HIV status, negotiating their
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first sexual experiences can be complex and the import-
ance of condom use may vary depending on cultural and
religious norms [19, 20]. For young people with PAH,
sexual onset will occur alongside their knowledge of
having a sexually transmittable, stigmatised medical
condition.
Sharing an HIV-positive status with others has the
potential to facilitate positive outcomes in the above
areas. It is now accepted that successful viral suppres-
sion (< 200 copies HIV RNA/ml) with ART prevents
HIV transmission to sexual partners (Undetectable =
Untransmittable; U = U) [21, 22]. In situations where
viral suppression has not been achieved, however,
sharing an HIV-positive status with partners may re-
duce onward HIV transmission, by fostering commu-
nication about safer sex. Indeed, sharing HIV status
with partners has been estimated to reduce risks of
onward HIV transmission by 18–61% [23, 24]. HIV
status sharing may also encourage a partner to
undergo testing, use prevention strategies such as
condoms, pre-exposure prophylaxis (PrEP) and post-
exposure prophylaxis (PEP), and engage in care/treat-
ment if needed [25].
Although young adults who have an undetectable viral
load may not have to share their status to prevent on-
ward HIV transmission, sharing has been shown to have
a number of personal benefits in addition to its public
health benefits [26]. Sharing may help to buffer HIV-
related stress and improve well-being [27, 28]. Being
open about one’s HIV status may facilitate obtaining so-
cial support from significant others such as families and
peers, which in turn is a prerequisite for constructive
coping, enhanced self-esteem and other health-
promoting behaviors [28]. Sharing of one’s HIV status
may also enhance ART adherence, due to greater adher-
ence support from partners, friends or family and a re-
duced need to hide medication use in situations where
sharing has not occurred [29, 30]. This is particularly
important even for young adults who have an undetect-
able viral load as they will only remain undetectable if
they continue to adhere to ART. Fear of sharing HIV
status is commonly cited as a barrier to ART adherence
in young people living with PAH [31]. There is also evi-
dence of lower levels of HIV status sharing being associ-
ated with poorer engagement with HIV care [32, 33].
Globally, there are low rates of sharing an HIV-
positive status with a partner, ranging from 39–97%
[34]. This may be even lower in young people with PAH.
Birungi, Obare, Mugisha, Evelia and Nyombi [35] re-
ported that only 38% of their sample of youth with PAH
in relationships (aged 15–19 years) had shared their HIV
status with their current partner. Lee and Oberdorfer
[36] found that 48% of their sample of adolescents (aged
13+) living with PAH had never shared their status to
anyone. Only 40% of young adults living with PAH in
the US reported sharing with all or most of their part-
ners in a recent study, and almost half (45%) reported
sharing with no partners when having unprotected sex
[25]. In a study in Uganda and Kenya, only one in five
participants (adolescents aged 13–17) reported having
shared their HIV status with their peers [28].
Sharing an HIV status carries a unique challenge for
young people with PAH with concerns about revealing
their mother’s (and other family members’) HIV status
[37]. Negative parental sharing attitudes, including direc-
tives to not share, may be internalised [37] with an at-
mosphere of secrecy and limits to open communication
about HIV affecting the young person at home, in their
community and in the clinic [38, 39]. The subjective dif-
ficulty of sharing one’s HIV status in young people with
PAH, particularly in relationships, has been frequently
reported, with a fear of rejection, a lack of confidence
about sharing (disclosure self-efficacy), and fear of sec-
ondary disclosure from the recipient to others cited as
barriers to sharing [37, 40–42].
There remain important risks of sharing ones’ HIV
status, including the threat of rejection, humiliation,
stigma and even violence [25, 43]. However, overall,
there may be more potential benefits of sharing ones’
HIV status. Hence, for other groups of people living with
HIV, there have been efforts to develop HIV status-
sharing interventions. Conserve et al. [34] reviewed in-
terventions promoting HIV sharing to sexual partners.
Three of the five studies included in this review (four of
which focused on MSM, the other minority women)
showed rates or frequencies of HIV sharing that were
greater in the intervention condition than the control
condition, with small-to-medium effect sizes reported.
Kennedy et al. [44] reviewed interventions promoting
HIV status sharing to any recipient in low- and middle-
income countries. Seven of the nine studies where out-
comes were reported showed a significantly greater level
of HIV sharing in the intervention compared with the
control arm, with small-to-medium effects. There are no
HIV status-sharing interventions specifically designed
for young people with PAH, or young people with HIV
more generally [45]. Facilitating sharing is often a small
component of multi-component interventions for youth
with HIV, but this component is rarely evaluated [46]. A
recent systematic review of interventions to improve re-
tention in HIV care and adherence to ART among youth
highlighted the need for further development and testing
of multi-faceted interventions, to address broader social
barriers to adherence and retention [47].
Consistent with the gaps in the evidence base outlined
above, there is a lack of sharing guidance to support
young people with PAH or professionals working with
this population [45]. The World Health Organisation
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(WHO) has called for work in this area, specifying the
need for interventions to help adolescent disclosure
decision-making, support caregivers and train providers
(WHO, 2018). There is evidence that young people with
HIV [48–50] and health care workers [51] would like
more HIV status-sharing support.
Given the gap in the evidence base, and the import-
ance of the issue, we aim to develop and test the
feasibility of a behavioural intervention to increase
sharing levels and satisfaction with sharing decisions
in perinatally infected young adults in the UK and
Uganda in a 30-month project. The appropriateness
of the intervention in high-income/low-prevalence
(e.g., UK) and low-income/high-prevalence (e.g.,
Uganda) contexts needs to be assessed, given evidence
of low rates of sharing in both. The target population
will be aged 18–25 years, due to higher rates of sexual
activity, with potentially more active consideration of
sharing than in younger populations, as well as higher
mortality and morbidity in this age group [12]. In
addition, in this age range, decisions about sharing
may be less constrained by others than during earlier
adolescence. The focus will be on sharing with any
recipient depending on participant preference. Enhan-
cing sharing with one category of recipient could fa-
cilitate sharing with other categories. For example,
increased sharing and communication with friends
and family has been shown to be associated with
sharing with a partner [25, 42].
We hypothesise that (1) the intervention will be feas-
ible, in relation to recruitment, retention and acceptabil-
ity and (2) participants in the intervention group will
have a higher rate of sharing in the previous 6 months at
follow-up than participants in a standard-of-care (SOC)
group.
Methods/design
Study settings
The study will take place in two countries (list of study
sites available on request):
1. UK. Participants will be recruited from five inner
city NHS clinics which provide services for young
people living with PAH across two cities, as well as
from one UK-based HIV charity.
2. Uganda. Participants will be recruited from a
not-for-profit organisation in one city, providing
HIV care to young people living with PAH ≥ 18
years.
Phase 1—intervention development and adaptation (12
months)
This phase will involve (1) assessing barriers and facilita-
tors to HIV status sharing, with questions informed by
an intervention development framework [52], (2) devel-
oping a theory of HIV sharing relevant to the study con-
texts, (3) developing intervention and recruitment
strategies, (4) carrying out formative assessment of inter-
vention components for feasibility, understanding and
acceptability, (5) manualising the intervention, (6) devel-
oping semi-structured interview guides, (7) developing a
fidelity measure for the intervention, (8) developing a
measure to describe standard of care, (9) training thera-
pists delivering the intervention, (10) developing
methods to assess intervention costs in phase 2 and (11)
developing and adapting measures of primary and sec-
ondary outcomes and other variables (e.g., ART adher-
ence self-efficacy). The latter task will involve producing
linguistically and culturally validated measures where
none exist for the Ugandan context, through translating
existing questionnaires/items and response options, back
translation by a different translator, reviewing of trans-
lated items by a local expert panel and cognitive inter-
viewing of ten young people taking part in phase 1 in
Uganda.
Individual assessments and focus groups will be used.
Participants for this stage will involve the following:
 Ten young people with PAH in the UK and ten in
Uganda:
 Inclusion criteria:
 Aged 18 to 29 years inclusive in the UK, and
18 to 25 inclusive in Uganda (the wider age
range in the UK reflects the greater difficulty
in recruiting from the population, given its
relatively smaller size compared with Uganda);
 Living with PAH;
 Knowledge of own HIV status;
 Able to give informed consent
 Exclusion criteria:
 Current serious mental health problems.
Clinician opinion will be sought regarding the
assessment of any mental health difficulties
that might render young people unsuitable for
the study;
 Moderate-to-severe learning disability/
executive functioning difficulties. Individuals
with clinically documented moderate-to-severe
cognitive difficulties will be excluded;
 Current serious physical health problems with
life expectancy < 12 months, according to
clinician opinion;
 Current participation in other psychosocial
intervention/support research
 Friends, family and partners of young people with
PAH in the UK (ten individuals) and in Uganda (a
further ten).
 Inclusion criteria:
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 Friends, family or partners of people currently
or recently aged 18–29 years living with PAH
in the UK, 18–25 years in Uganda;
 Awareness of the HIV status of the young
person with PAH;
 Five professionals working with young people living
with PAH in the UK and five in Uganda
 Inclusion criteria:
 Current or recent involvement in the care of
the people aged 18-25 living with PAH.
Phase 2—main study: feasibility trial
Study design
This component of the study uses a multi-site rando-
mised feasibility design. Participants will be randomised
to either the intervention or standard of care. Assess-
ments will be carried out at three time points—pre-
intervention/baseline (for both conditions), post-
intervention (at the end of the final session, only for the
intervention condition), and 6-month follow-up (6
months from baseline, both conditions). See Fig. 1 for a
flow diagram of the Phase 2 study design.
Sample
The sample size will be 94 per condition (intervention
or standard of care; 188 participants in total: 47 in each
condition in each country). This sample size has been
chosen to allow for study attrition so that at least 64 par-
ticipants per condition will be retained in the study.
Sample size calculation
The sample size of 32 in each condition in each country
has been chosen to both assess primary outcomes, and
to be sufficient to enable differences of between 0.5 and
1 standard deviation to be observed between conditions
with 80% statistical power across secondary outcomes
(e.g., changes in rates of HIV status sharing). Half a stan-
dardised difference would require 64 per condition, and
one standard deviation difference would require 16 per
condition.
Inclusion criteria
The following are included in the study:
 Aged 18 to 25 years inclusive;
 Living with PAH;
 Receiving HIV care at study sites;
 Knowledge of own HIV status
Exclusion criteria
The following are excluded in the study:
 Current serious mental health problems. Clinician
opinion will be sought regarding the assessment of
any mental health difficulties that might render
young people unsuitable for the study;
 Moderate-to-severe learning disability/executive
functioning difficulties. Individuals with clinically
Fig. 1 Flow diagram of Phase 2 study design
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documented moderate-to-severe cognitive difficul-
ties will be excluded.
 Current serious physical health problems with life
expectancy of < 12 months, according to clinician
opinion;
 Inability to understand or communicate in English
(UK) or either English or Luganda (Uganda)
according to clinician opinion
 Current participation in other psychosocial
intervention/support research
 Participation in phase 1 of this study
 Participation of another individual within the
household
Intervention condition
The intervention condition will consist of four ses-
sions (90 min per session) delivered in a mixed
group/individual format (three group sessions includ-
ing seven or eight participants/one individual session);
professionally led (therapist one); mixed gender; face-
to-face; with peer mentor involvement (therapist two)
and follow-up support. These features were preferred
by clinic attendees in survey of 57 young people with
PAH in the UK [53] and were seen as feasible in a
second survey of 16 professionals working with this
population in the UK [54].
The intervention will aim to develop motivation and
skills for HIV status sharing, increase HIV status sharing
self-efficacy, decrease anxiety about HIV sharing and in-
crease satisfaction with HIV status sharing decision-
making. Motivational interviewing (MI) and Cognitive
behavioural therapy (CBT) will guide the intervention.
The intervention will be delivered by two therapists in
each country. One will be a health professional (not a
mental health specialist). The other will be a peer
worker.
The content of the intervention is based on models of
HIV disclosure decision-making and HIV disclosure
anxiety [55–58] and existing evidence of HIV status-
sharing correlates, barriers and facilitators [25, 28, 59].
In particular, disclosure attitudes, normative beliefs, self-
efficacy, planning and support are argued to be import-
ant proximal determinants of HIV status sharing. These
factors are suggested to be influenced by more distal fac-
tors: personal values and HIV stigma.
The content of specific sessions will be as follows:
 Session 1—Engaging: ground rules, living with HIV,
previous experiences of HIV sharing (and evaluation
of these experiences), defining HIV status sharing
(as a process), understanding HIV status-sharing
anxiety, risks and benefits of disclosure and non-
disclosure in specific situations and with different re-
cipients, and values clarification exercise
 Session 2—Focusing and evoking: HIV sharing
wants and needs, eliciting and reinforcement of
personal HIV-sharing decision rules, exploring dis-
crepancy between decision rules/current HIV status
sharing and values, and examining evidence for HIV
status-sharing anxiety
 Session 3—Developing HIV status-sharing skills:
identifying barriers and facilitators to HIV status
sharing, responding to others’ reactions to HIV sta-
tus sharing, HIV sharing strategies; developing HIV-
sharing decision (if…then) rules, HIV status-sharing
communication skills, use of social support (identify-
ing safe/special people to disclose to), managing HIV
status-sharing anxiety (challenging anxious think-
ing), HIV-sharing hierarchies including level of HIV
sharing and level of anxiety about response, setting
HIV-sharing goals, and planning to disclose (how,
where and when)
 Session 4—Individual goal setting and planning:
personal feedback from assessment; assessing HIV-
sharing readiness; goal setting; who, how and when
to disclose (action planning, using HIV-sharing deci-
sion aid); coping with HIV-sharing consequences
over time (coping planning); using pre and post
HIV-sharing support for self-disclosure recipient;
safer sex skills (including condom use); considering
nature of relationship with potential recipient, level
of HIV sharing, and method of HIV sharing; ways to
minimise risk of adverse outcomes/overcome bar-
riers/respond to adverse responses; accepting possi-
bility of adverse outcomes; and producing a
personalised HIV-sharing plan
We will use role play, modelling, cognitive restructur-
ing and behavioural exposure techniques, with both
video material and group discussions integrated with
interactive exercises. We will aim to space out the ses-
sions to allow reflection on HIV sharing or actual shar-
ing to take place between sessions. Follow-up emotional,
informational and problem-solving support (in the 6
months from baseline to the follow-up data point) from
a peer worker will be provided for both young people
exposed to the intervention and people whom they have
disclosed to. This will involve the use of both phone and
online/social media options [60].
Standard-of-care condition
The UK NHS sites and the Uganda site have dedicated
clinics for young people growing up with HIV who have
previously been in paediatric care, with peer support and
professional psychosocial support available in the
Uganda site and in the majority of the UK NHS sites. In
these clinics, young people can discuss HIV sharing with
their multidisciplinary team, attend with their partner,
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and have access to a range of other services (e.g., HIV
testing, PrEP and condom provision). Standard of care
in both countries, however, is for there to be no routine
or structured psychosocial intervention to facilitate HIV
sharing or sharing decision-making.
Measures
Information on viral load and CD4 counts, as available,
will be collected from clinic records. Scales in English
will be translated into Luganda during the intervention
development phase and adapted as necessary.
Primary outcome measure
Study recruitment and retention
The feasibility of the intervention will be assessed in
relation to study recruitment, retention and acceptabil-
ity. Recruitment and retention rates will be calculated
for each site and for each condition. In addition, post-
intervention rating scales will be administered to assess
acceptability for participants in the intervention condi-
tion (satisfaction, intention to continue to use, and per-
ceived appropriateness of the intervention) [61].
Secondary outcome measures
The range of outcomes reflect the likely diversity of the
sample and the potential complexity of relationships be-
tween sharing, its predictors and consequences.
HIV disclosure behaviour
Self-reported HIV-sharing events will be assessed
through recording the frequency of new disclosures (full
or partial; first hand or second hand with consent) in the
last 6 months to partners, friends and family, and any
change in the proportion of social network disclosed to.
For each disclosure, recipient and relationship charac-
teristics, perceived satisfaction with HIV-sharing deci-
sion, and the nature of the recipient’s response will be
assessed. In addition, for those individuals in a partici-
pant’s social network not disclosed to, satisfaction with
sharing decisions and disclosure intention will be mea-
sured. Any social harms occurring as a result of sharing
will be recorded. We will develop this measure with ref-
erence to existing relevant measures [62–65]. At the
follow-up time point for those in both conditions, we
will also ask about whether any disclosure support was
sought from professionals or social contacts during the
previous 6months.
ART adherence
Biological correlates of ART adherence (most recent
viral load and CD4 count, if available) will be collected
from participants’ clinical records. Adherence behaviour
will be assessed by the CASE adherence index [66],
which has been used in Uganda [28]. The CASE adher-
ence index contains three questions relating to difficulty
in taking ART medication on time (scored on a scale
from 4—never to 1—all of the time), frequency of
missed doses (scored on a scale from 1—everyday to 6—
never) and time since most recent missed dose (scored
on a scale from 1—within the past week to 6—never). Its
reliability and validity has been assessed by estimating
the degree of sensitivity and specificity to changes in
three-day adherence self-report and comparing it to
changes in HIV virologic outcomes and CD4 counts
across time [66].
Psychological well-being
The 6-item psychological domain from the World
Health Organisation Quality of Life brief questionnaire
(WHOQOL BREF) [67] will be used. This measure has
been translated into Luganda with good evidence of reli-
ability and validity [68]. It includes questions on bodily
image and appearance, negative feelings, positive feel-
ings, self-esteem, spirituality/religion/personal beliefs,
and thinking/concentration, which are answered on a 5-
point scale (e.g. from 1—not at all to 5—completely). As
well as measuring wellbeing as an outcome of the inter-
vention, this variable may also mediate changes in other
outcomes.
Social support
The 6-item Social Support Questionnaire Short form
(SSQ6) [69] will be used. For each of the 6 items (e.g.
Whom can you really count on to help you feel more re-
laxed when you are under pressure or tense?), respon-
dents indicate the number of people available to provide
support and then rate the overall level of satisfaction
with the support given in each of the areas from 6—very
satisfied to 1—very dissatisfied. A longer form of this
measure has been used with young people living with
HIV in Uganda [70]. As well as measuring social support
as an outcome of the intervention, this variable may also
mediate changes in other outcomes.
Hope
The 6-item State Hope Scale will be used [71]. The
State Hope Scale offers a brief, internally consistent, and
valid self-report measure of ongoing goal-directed think-
ing [71]. It includes items such as “There are lots of ways
around any problem that I am facing now”, and is scored
on an 8-point Likert scale from 1 (definitely true) to 8
(definitely false).
Sexual outcomes
The frequency and rate of unprotected sexual inter-
course will be calculated for casual and regular partners
with self-report data. Pregnancy, perceived partner status
and PrEP use will also be recorded.
Decisional conflict scale
The 4-item decisional conflict scale will be used in re-
lation to decisions to share [72]. The four items are the
following: feeling uncertain (Sure of myself), feeling in-
formed (Understand information), feeling clear about
values (Risk-benefit ratio), and feeling supported in
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decision making (Encouragement). A response of yes
scores 1 and a response of no scores 0; a score of < 4 is a
positive result for decisional conflict. The internal
consistency of the scale has been shown to be moderate
in English-speaking treatment-option patients [72], and
the scale has shown adequate psychometric properties in
a primary care population with a low prevalence of clin-
ically significant decisional conflict [73].
Measurement of hypothesised mediators
HIV disclosure cognitions and affect
We will translate and adapt the 18-item HIV dis-
closure cognitions and affect scale, which has shown
good preliminary evidence of reliability and validity in
adolescents with PAH [74]. This scale contains three
subscales representing negative disclosure attitudes
and feelings, disclosure self-efficacy and positive dis-
closure attitudes and feelings. An example item is, “I
am worried they will tell others”. Items are scored on
a 5-point Likert scale from strongly disagree to
strongly agree. We will develop an HIV disclosure
intention item from existing measures [25, 75].
HIV disclosure planning
HIV disclosure planning will be assessed by asking two
questions relating to action and coping planning. These
questions will be adapted from questions used in the
study with adolescents with PAH in the UK, from which
a novel way of coding HIV status-sharing planning was
developed [76].
ART adherence self-efficacy
The 14-item behavioural skills subscale of the Life
Windows Adherence Questionnaire [77] will be used.
This has shown good reliability in different contexts, in-
cluding in sub-Saharan Africa [78–80]. An example item
is, “How hard or easy is it for you to remember to take
your HIV medications?”. Response options are 1 (cannot
do at all) to 5 (certain you can do).
HIV stigma
The three-item negative self-image subscale from the
short form of the HIV stigma scale will be used [81].
This has shown evidence of good reliability. An example
item is “I feel I’m not as good a person as others because
I have HIV”, and responses are on a 4-point Likert scale,
ranging from strongly disagree (1) to strongly agree (4).
Measurement of background variables
Previous HIV disclosure
In addition to recording individual disclosure events in
the previous 6 months (above), and the proportion of
friends, family and partners disclosed to [63–65], partici-
pants will be asked about lifetime HIV-sharing
frequency.
Personal values
The 24-item Agentic and Communal Value Scale
(ACV) will be used [82]. The 24 items include 12
Agency items (e.g. wealth, pleasure, ambition) and 12
Communion items (e.g. forgiveness, trust, politeness)
which are rated in terms of the relative importance of
each value as “a guiding principle in my life” from not
important to me (1) to highly important to me (9). The
measure has been used with young adults [83, 84], in-
cluding those with PAH [85] and has evidence of good
reliability.
Demographic and clinical variables
Demographic variables (current age, ethnicity, gender,
parental loss, relationship status, substance use, preg-
nancy, housing, location, living situation, education/oc-
cupation, income/socio-economic status, sexuality) and
clinical variables (age at paediatric HIV disclosure, previ-
ous psychosocial interventions, clinic, clinic attendance,
regimen, side effects, comorbid health conditions) will
be assessed. We will record whether psychosocial sup-
port has been offered to the participants over the course
of the study in both countries and the nature of any dis-
cussions about HIV sharing in standard care. This infor-
mation will be obtained from participants (during the
follow-up assessment) and clinic staff (using standard-
of-care monitoring forms).
Phase 2—Sub-study: qualitative interviews
Face-to-face interviews with ten participants in the UK
and ten participants in Uganda will be conducted post-
intervention (immediately after the final intervention
session, and at the 6-month follow-up) to aid in the as-
sessment of feasibility and to clarify potential causal
mechanisms of the intervention. Individuals will be sam-
pled purposively from both conditions (interventions
and standard of care) to ensure that a range of partici-
pant characteristics (e.g. age, gender, level of HIV shar-
ing) are represented.
Procedure
Phase 1
Sampling and identification
Young people with PAH meeting the inclusion criteria
will be identified by clinicians and representatives of
support organisations with an attempt to sample those
with a range of levels of onward HIV disclosure and with
a range of demographic characteristics. Friends, family
and partners of young people with PAH will be identi-
fied by the young person with PAH. Professionals work-
ing with young people with PAH will be identified by
the research team, attempting to sample across a range
of clinics and support organisations.
Approach and provision of study information
Young people identified will be informed about the
study verbally by a named clinician or support
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organisation representative by phone or at their next
clinic/support organisation appointment. If they are in-
formed by phone and are interested in the study, they
will be asked permission for their professional to pass on
their contact details to the study coordinator. The study
coordinator will contact the young person to arrange a
time to meet and to go through the participant informa-
tion sheet. If the young person is informed at their next
clinic/support organisation appointment, they will be
given the participant information sheet by the profes-
sional who will either go through this with them or ask
the study coordinator to do this, if they are available. If
the young person is interested in taking part, having
gone through the participant information sheet with the
professional, their details will be passed on to the study
coordinator.
Young people will be asked whether they can identify
any friends, family members or regular partners who
they think might like to take part in the study. The
young person will be asked to discuss the project with
them and to provide the study coordinator’s details. If
friends, family or partners are interested in finding out
more about the study, they will be asked to contact the
study coordinator by phone. If they are interested, they
will arrange a time to meet the study coordinator to go
through the participant information sheet. For profes-
sionals working with young people with PAH, the study
coordinator will inform them about the study by phone.
If they are interested, they will arrange a time to meet
the study coordinator to go through the participant in-
formation sheet.
Consent and participation
Written informed consent will be sought by the study
coordinator or a member of the clinical team. Partici-
pants will be asked to offer their consent for all elements
of this phase of the study, despite the fact that they may
not be asked to take part in all activities. The right to
withdraw will be stressed. One copy of the signed con-
sent form will be given to the participant and one will
be kept by the study coordinator to file in the central
study register. The participant will be enrolled and then
they will participate in the study. Travel expenses will be
paid and participant payments will be made to non-
professional participants and receipts will be kept by the
study coordinator.
Phase 2: main study
Sampling, identification, screening and randomisation
A sampling frame will be constructed for each site by
a named clinician applying the inclusion and exclusion
criteria to their clinic population. A record of young
people who are not eligible will be kept in a site study
log to ensure that these individuals are not screened or
approached in the future. Anonymised details of those
not eligible (with reasons) will be passed to the study
coordinator to record in the central study register to en-
able a study flow diagram to be compiled. The details of
those eligible to participate will be provided to the study
coordinator. Simple random sampling (without replace-
ment) will be used by the study coordinator to identify
which young people are approached to take part in the
study from among those eligible across the sites in the
country (using Research Randomizer: https://www.ran-
domizer.org/).
Approach and provision of study information
If young people are eligible and randomly selected
to be approached, the study coordinator will inform a
named clinician at each site. The young person will
be informed about the study verbally by the named
clinician by phone, text or email, or at their next
clinic appointment. If the young person expresses an
interest in the study, they will be given further infor-
mation by either the clinician or the study coordin-
ator (the latter after permission for the clinician to
pass on their contact details to the study coordinator
has been sought). If the study coordinator is the per-
son providing further information, the study coordin-
ator will contact the young person to arrange a time
to meet and to go through the participant informa-
tion sheet. If the clinician is the person providing fur-
ther information, the young person will be given the
participant information sheet by the clinician who will
go through this with them. If the young person is in-
terested in taking part, having gone through the par-
ticipant information sheet with the clinician, their
details will be passed on to the study coordinator. If
potential participants are not interested in taking part,
this will be recorded in the site study log by the
named clinician and anonymised information (with
the reason for refusal) will be provided to the study
coordinator to record in the central study register.
This will help to determine the study response rate.
Consent
Written informed consent will be sought by the clin-
ician or the study coordinator in each country. Consent
documents will be translated into Luganda in Uganda,
with the participants in Uganda having the choice be-
tween English or Luganda documents. Young people will
be asked to offer their consent for both the main study
and the sub-study at the same time, despite the fact that
only a proportion of those taking part in the main study
will be asked to take part in the sub-study. Consent will
be sought for access to clinic data. Consent will also be
sought for young people to be contacted before their
follow-up assessment as a reminder and after this assess-
ment if they have not attended. One copy of the signed
consent form will be given to the participant, one for the
clinical notes, and one will be kept by the study coordin-
ator to file in the participant’s personal study register.
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Enrolment, randomisation (both conditions) and
baseline assessments (standard-of-care condition
only)
The study coordinator will arrange the enrolment visit
at the end of the consent process if the study coordin-
ator has taken consent. If the clinician has taken con-
sent, the study coordinator will contact the participant
to arrange the enrolment visit. If the study coordinator
and the participant are able to carry out the enrolment
process at the same time as consent is obtained, this will
be offered. At the enrolment visit, the participant will be
enrolled into the study and given a study ID. Personal
information will be recorded by the study coordinator in
the participant’s personal study register (name, contact
details, etc.) and non-identifiable information will be re-
corded in the central study register (study ID, date of en-
rolment, etc.).
Stratified block random allocation to condition by
country/site (UK inner city NHS clinics and Uganda)
will be used. There will be 12 blocks of either 15 or 16
participants per block (six blocks in Uganda, five blocks
in London and one block in Birmingham). Computer-
generated randomisation will be used using the Research
Randomizer. The randomisation will be carried out by
the study PI in the UK and the site PI in Uganda. Alloca-
tion will be concealed from the study coordinator in
each country through the use of sequentially numbered
opaque envelopes. The study coordinator will inform the
participant which condition that they have been allo-
cated to.
If the participant is in the standard-of-care condition,
the baseline assessment will then be administered by the
study coordinator, who will also record clinical informa-
tion from the clinical notes or database for participants
in this condition. Travel expenses will be paid to partici-
pants in both the intervention and the standard-of-care
conditions if any have been incurred and a receipt will
be kept.
Baseline assessment (intervention condition) and
intervention
If the participant has been allocated to the interven-
tion condition, their details will be passed to the
intervention therapists, who will liaise with the study
coordinator and participant about the timetabling of
the baseline assessment and intervention sessions.
The participant will be asked for their preference
about when they would like intervention sessions to
take place. The therapists will also explore any con-
cerns that the participant has about the intervention.
The baseline assessment will be administered by the
study coordinator immediately prior to the first inter-
vention session. The study coordinator will also rec-
ord clinical information from the clinical notes or
database.
All four intervention sessions will take place within a
month time period. It is hoped that intervention partici-
pants will attend all four sessions, but they will be
allowed to move on the next session if they have missed
a previous one. All intervention sessions will be taped.
Session attendance will be recorded by the therapists. A
random selection of 10% of the sessions will be reviewed
by one from the research team for fidelity to the inter-
vention (using an intervention checklist), and feedback
will be offered to the therapists based on this review (as
well as problem-solving supervision). Travel expenses
will be paid to participants by the therapists if any have
been incurred and a receipt will be kept and passed on
to the study coordinator. Participants will be remuner-
ated for each intervention session.
Post-intervention measurement
This will take place for the intervention group only. It
will take place at the end of the final session. This will
be carried out by the study coordinator. Travel expenses
will be paid if any have been incurred and participant
payments made, and receipts will be kept by the study
coordinator.
Follow-up measurement
This will occur 6 months after the baseline measures
have been completed for both participants in the inter-
vention condition and the standard-of-care condition
and will be conducted by the study coordinator. We will
use participant reminders and prompts (provided by the
study coordinator) to minimise attrition. Participants
will be contacted 1 month and 1 week before the sec-
ond/third study visit is due (by phone/SMS), and at-
tempts will be made to arrange the location and time of
this visit. Participants will be reimbursed for their time
and for any travel expenses incurred. Receipts will be
kept by the study coordinator.
After the follow-up assessment
The following activities will take place after the follow-
up assessment (by the study coordinator).
 Attempts to track participants if they have not
attended their follow-up visit (by phone/SMS)
 Obtaining clinic data
Phase 2: sub-study
Sampling and identification
For the sub-study, participants in both conditions will
be identified by the study coordinator to ensure that a
range of characteristics are represented (e.g. age, location
and sex) at each interview time point (post-intervention
and follow-up).
Approach
The study coordinator will contact young people who
have been identified to ask whether they would like to
participate in the sub-study. If they are willing to
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participate, this will be recorded in their personal study
register and the central study register. The study coord-
inator will arrange a time and location for the interview
with the participant. If potential participants are not in-
terested in taking part, this will be recorded in anon-
ymised form (with the reason for refusal) in the central
study register. This will help to determine the sub-study
response rate.
Participation
The study coordinator will provide a reminder a week
before the interview (by phone/SMS). Participants will
be reimbursed for their involvement in the sub-study
and for travel expenses incurred, and receipts will be
kept by the study coordinator.
After the arranged interview
Attempts to track participants will be made by the
study coordinator if they did not attend their interview
visit (by phone/SMS).
Data management and analysis
Confidentiality of all information will be assured to all
participants unless they report something that suggests
that they or someone else whom they identify might be
at risk of serious harm. In this case, a member of the re-
search team may need to speak to their clinical team so
that they are able to provide appropriate support. All
survey and interview data will be de-identified and
treated as strictly confidential. Personally identifiable
data will be stored anonymously in locked filing cabinets
at each study site or digitally in an encrypted file. Data
will be identified only by the participant’s study ID and
will be password protected with only the project investi-
gators having access.
Phase 1
The qualitative intervention development and interven-
tion process evaluation will be informed by thematic
analysis [86]. Individual and focus group interviews will
be recorded and initial codes will be generated from the
audio data. Themes will be developed and reviewed from
the initial codes. These themes will then be defined and
named. These findings will be used to inform the inter-
vention sessions in phase 2.
Phase 2: main study
Exploration of data will be conducted via pooled analysis
as well as analysing by country, although the former is
necessarily preliminary given issues of statistical power.
The evaluation will present descriptive data on recruit-
ment and retention rates and acceptability. We antici-
pate a retention rate of 68% based on previous studies
[44]. If the retention rate in the study in each country is
68%, the 95% confidence intervals of this rate for each
country (n = 94) would be ± 9.5% (i.e. confidence interval
width of 19%). We feel that this is an acceptable level of
precision to inform the planning of a future RCT and
will be sufficient to answer the study research questions.
Criteria for moving to a full trial will be based on a
range of criteria, including acceptability (from individual
interviews and rating scales), demand (based on recruit-
ment and retention rates), implementation, adaptation
(across the two settings) and limited efficacy. Reasons
for refusal to enrol in the study will be assessed and
comparisons will be made between participants and both
clinic and national data on the population to assess the
likelihood of selection bias.
For secondary outcomes, descriptive analysis will be
conducted on frequencies, percentages, central tendency
and variability of data. Missing data will be imputed if
appropriate. The distribution of missing data will be
assessed with Little’s Missing Completely at Random
Test [87] before using Expectation Maximisation to im-
pute missing data if the proportion of missing data is
small. For multi-item measures developed or adapted for
this study, Principal Components Analysis (PCA) will
first be carried out using both orthogonal (varimax) and
oblique (oblimin) rotations. Scree plots will be examined
to determine the number of factors to extract and ana-
lyses will be re-run specifying the number of factors.
Items will be dropped from the scale if factor loadings
are low or if they load on more than one factor. If any
items are dropped, PCA will be re-run. Cronbach’s alpha
will calculated for the final total scale and its subscales,
and item-total correlations will be examined.
The effect of the intervention on secondary outcomes
will be carried out separately for each country. Two
tailed tests will be used. Exploration via multivariate
analysis will also be carried out if there is sufficient data
to support this approach. Sufficient data refers both to
missing data (although we will impute data if this is min-
imal, e.g., <5%) and to the number of observations (e.g.,
if attrition results in a lack of statistical power to investi-
gate multivariate relationships).
Independent t tests (where parametric assumptions
were met) and chi-squared tests will be used to compare
baseline characteristics of those retained in the study to
those lost to follow up to examine whether there are any
systematic differences between these groups. We will in-
terpret our findings on secondary outcomes in light of
this ‘lost to follow up’ analysis. We will aim to obtain
follow-up data from all participants enrolled in the study
regardless of the extent of involvement in intervention
activities.
The extent to which participants in the intervention
condition naturally use HIV disclosure ‘change talk’ (lan-
guage indicating preparation for and commitment to
disclosing their HIV status) in the final individual ses-
sion will be calculated using the Motivational
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Interviewing Skills Code (MISC) 2.5 coding manual [88].
The relationship between the frequency of disclosure
change talk and any HIV status sharing at the 6-month
data point will be calculated using logistic regression
analysis.
Phase 2: sub-study
The analysis of the qualitative data will be undertaken
using thematic analysis [86]. Findings will be compared
with the quantitative results to add further depth of un-
derstanding to the evaluation of the proposed
intervention.
Advisory groups
Two advisory groups will be formed (one in the UK and
one in Uganda) to consult with on the progress of the
study. The groups will involve key stakeholders, includ-
ing young people living with PAH, partners, friends and
family members, health care workers, health academics,
and representatives from support organisations and pol-
icy making organisations. We will aim to recruit individ-
uals with a spread of knowledge and expertise. The
advisory group meetings will take place on four occa-
sions over the life of the study—at the start of phase 1,
prior to phase 2 recruitment, during phase 2 recruit-
ment, and at the end of the study. The terms of refer-
ence of the groups will include the following:
 Providing advice on recruitment and retention
 Providing advice on the development of strategic
partnerships, engaging stakeholders, and
dissemination
 Providing a forum for discussion of key study issues
 Promoting the study
 Providing advice on intervention content
Dissemination
The study protocol has been registered and is available
on the ISRCNT registry (https://doi.org/10.1186/
ISRCTN31852047). The results will be disseminated to
all participants, their friends and families, researchers,
healthcare providers, support organisations, policy
makers and the funding body through summary docu-
ments, presentations, through a study website (http://pc.
rhul.ac.uk/sites/headsup/) and a full report. Training
workshops and seminars will be conducted at the end of
the study to disseminate and discuss findings; a video
describing the findings briefly will be prepared, and a
free webinar will be organised to allow questions to be
asked about the research. The findings will also be sub-
mitted to peer-reviewed scientific journals and presented
at conferences to reach researchers and healthcare
professionals.
Discussion
Young people with PAH face challenges to positive well-
being, reducing the risk of onward HIV transmission
and adhering consistently to ART medication. The shar-
ing of one’s HIV status may assist in the process of cop-
ing with these challenges and, therefore, supporting
young people with PAH with their decisions to share
their status should be a priority. The HEADS-UP study
is the first feasibility study to focus on HIV sharing
among young adults living with PAH. The current inves-
tigation will build upon and extend the established evi-
dence base supporting the potential benefits of increased
sharing among young adults with PAH [29]. The study
is unique in its inclusion of young people from both
high-income/low-prevalence and low-income/high-
prevalence contexts. This study will be the first to ad-
dress important gaps in understandings of acceptable
and feasible ways of delivering sharing support for young
people with PAH. The findings will inform the actions
needed to enhance HIV status sharing and improve
young people with PAH’s satisfaction with their sharing
decision-making.
Potential future implications
Findings from this feasibility study may inform the man-
agement of HIV sharing for young people living with
PAH and will inform the development of a full RCT, if
the intervention is feasible and acceptable. Outcomes of
this study will provide valuable information to guide de-
velopment and implementation of HIV disclosure inter-
vention policy and strategies. The study team, consisting
of health professionals and researchers with substantial
experience of working with young people with PAH in
the UK and Uganda, is uniquely positioned to develop
and disseminate such an intervention.
Trial status
The trial began recruitment of participants for phase 1
in the UK in September 2019, and in Uganda in October
2019. We expect to recruit the full sample for phase 1
near the end of March 2020. Phase 2 recruitment will
begin in August 2020 in the UK and in October 2020 in
Uganda, and we anticipate reaching our recruitment tar-
get by July 2021.
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